CN Patent

CN103172641B — 杂环胺基烷氧基取代的喹唑啉衍生物及其用途

Assigned to SHANGHAI FENGHUA PHARMACEUTICAL CO Ltd · Expires 2014-06-11 · 12y expired

What this patent protects

一种结构如下的杂环胺基烷氧基取代的喹唑啉衍生物及其药学上可接受的盐，具有抑制受体酪氨酸激酶EGFR的活性，可用于与ErbB家族的受体酪氨酸激酶表达相关的癌症的治疗。

USPTO Abstract

一种结构如下的杂环胺基烷氧基取代的喹唑啉衍生物及其药学上可接受的盐，具有抑制受体酪氨酸激酶EGFR的活性，可用于与ErbB家族的受体酪氨酸激酶表达相关的癌症的治疗。

Drugs covered by this patent

cabozantinib-s-malate (CABOZANTINIB S-MALATE)

Patent Metadata

Patent number: CN103172641B
Jurisdiction: CN
Classification: —
Expires: 2014-06-11
Drug substance claim: No
Drug product claim: No
Assignee: SHANGHAI FENGHUA PHARMACEUTICAL CO Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.